| pubmed-article:20976142 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20976142 | lifeskim:mentions | umls-concept:C0013030 | lld:lifeskim |
| pubmed-article:20976142 | lifeskim:mentions | umls-concept:C0870883 | lld:lifeskim |
| pubmed-article:20976142 | lifeskim:mentions | umls-concept:C0047556 | lld:lifeskim |
| pubmed-article:20976142 | lifeskim:mentions | umls-concept:C0949370 | lld:lifeskim |
| pubmed-article:20976142 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:20976142 | pubmed:dateCreated | 2010-10-26 | lld:pubmed |
| pubmed-article:20976142 | pubmed:abstractText | Dopamine (3-hydroxytyramine) is a well-known catecholamine neurotransmitter involved in multiple physiological functions including movement control. Here we report that the major extracellular metabolite of dopamine, 3-methoxytyramine (3-MT), can induce behavioral effects in a dopamine-independent manner and these effects are partially mediated by the trace amine associated receptor 1 (TAAR1). Unbiased in vivo screening of putative trace amine receptor ligands for potential effects on the movement control revealed that 3-MT infused in the brain is able to induce a complex set of abnormal involuntary movements in mice acutely depleted of dopamine. In normal mice, the central administration of 3-MT caused a temporary mild hyperactivity with a concomitant set of abnormal movements. Furthermore, 3-MT induced significant ERK and CREB phosphorylation in the mouse striatum, signaling events generally related to PKA-mediated cAMP accumulation. In mice lacking TAAR1, both behavioral and signaling effects of 3-MT were partially attenuated, consistent with the ability of 3-MT to activate TAAR1 receptors and cause cAMP accumulation as well as ERK and CREB phosphorylation in cellular assays. Thus, 3-MT is not just an inactive metabolite of DA, but a novel neuromodulator that in certain situations may be involved in movement control. Further characterization of the physiological functions mediated by 3-MT may advance understanding of the pathophysiology and pharmacology of brain disorders involving abnormal dopaminergic transmission, such as Parkinson's disease, dyskinesia and schizophrenia. | lld:pubmed |
| pubmed-article:20976142 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20976142 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20976142 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20976142 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20976142 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20976142 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20976142 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20976142 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20976142 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20976142 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20976142 | pubmed:issn | 1932-6203 | lld:pubmed |
| pubmed-article:20976142 | pubmed:author | pubmed-author:CaronMarc GMG | lld:pubmed |
| pubmed-article:20976142 | pubmed:author | pubmed-author:MasriBernardB | lld:pubmed |
| pubmed-article:20976142 | pubmed:author | pubmed-author:ZhangXiaodong... | lld:pubmed |
| pubmed-article:20976142 | pubmed:author | pubmed-author:SalahpourAliA | lld:pubmed |
| pubmed-article:20976142 | pubmed:author | pubmed-author:BarakLarry... | lld:pubmed |
| pubmed-article:20976142 | pubmed:author | pubmed-author:GainetdinovRa... | lld:pubmed |
| pubmed-article:20976142 | pubmed:author | pubmed-author:BeaulieuJean-... | lld:pubmed |
| pubmed-article:20976142 | pubmed:author | pubmed-author:SotnikovaTaty... | lld:pubmed |
| pubmed-article:20976142 | pubmed:author | pubmed-author:EspinozaStefa... | lld:pubmed |
| pubmed-article:20976142 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20976142 | pubmed:volume | 5 | lld:pubmed |
| pubmed-article:20976142 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20976142 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20976142 | pubmed:pagination | e13452 | lld:pubmed |
| pubmed-article:20976142 | pubmed:dateRevised | 2011-3-8 | lld:pubmed |
| pubmed-article:20976142 | pubmed:meshHeading | pubmed-meshheading:20976142... | lld:pubmed |
| pubmed-article:20976142 | pubmed:meshHeading | pubmed-meshheading:20976142... | lld:pubmed |
| pubmed-article:20976142 | pubmed:meshHeading | pubmed-meshheading:20976142... | lld:pubmed |
| pubmed-article:20976142 | pubmed:meshHeading | pubmed-meshheading:20976142... | lld:pubmed |
| pubmed-article:20976142 | pubmed:meshHeading | pubmed-meshheading:20976142... | lld:pubmed |
| pubmed-article:20976142 | pubmed:meshHeading | pubmed-meshheading:20976142... | lld:pubmed |
| pubmed-article:20976142 | pubmed:meshHeading | pubmed-meshheading:20976142... | lld:pubmed |
| pubmed-article:20976142 | pubmed:meshHeading | pubmed-meshheading:20976142... | lld:pubmed |
| pubmed-article:20976142 | pubmed:meshHeading | pubmed-meshheading:20976142... | lld:pubmed |
| pubmed-article:20976142 | pubmed:meshHeading | pubmed-meshheading:20976142... | lld:pubmed |
| pubmed-article:20976142 | pubmed:meshHeading | pubmed-meshheading:20976142... | lld:pubmed |
| pubmed-article:20976142 | pubmed:meshHeading | pubmed-meshheading:20976142... | lld:pubmed |
| pubmed-article:20976142 | pubmed:meshHeading | pubmed-meshheading:20976142... | lld:pubmed |
| pubmed-article:20976142 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20976142 | pubmed:articleTitle | The dopamine metabolite 3-methoxytyramine is a neuromodulator. | lld:pubmed |
| pubmed-article:20976142 | pubmed:affiliation | Department of Neuroscience and Brain Technologies, Italian Institute of Technology, Genova, Italy. | lld:pubmed |
| pubmed-article:20976142 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20976142 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:20976142 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| entrez-gene:13162 | entrezgene:pubmed | pubmed-article:20976142 | lld:entrezgene |
| entrez-gene:111174 | entrezgene:pubmed | pubmed-article:20976142 | lld:entrezgene |
